precigen - Search News

News

Precigen, FDA and immunotherapy

Precigen shares jump after US FDA approves first therapy for rare respiratory disease

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for the condition, which typically requires frequent surgeries, sending the company's shares soaring 83% on Friday.

· 1d · on MSN

Precigen surges on FDA approval for immunotherapy

pharmaphorum · 1d

FDA clears Precigen's rare tumour immunotherapy

TipRanks on MSN1d

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Fierce Pharma1d

Precigen scores FDA nod for first-ever treatment for HPV-related disorder

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease that causes benign tumors, most commonly in the voice box, and can force ...

Precigen: This Billion-Dollar Approval Is Still Undervalued

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

Why Is Precigen Stock Surging On Friday?

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad.

Fintel on MSN1d

JP Morgan Upgrades Precigen (PGEN)

Fintel reports that on August 15, 2025, JP Morgan upgraded their outlook for Precigen (NasdaqGS:PGEN) from Underweight to ...

TipRanks on MSN2d

Precigen trading halted, news pending

EDT Precigen (PGEN) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results